|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| US State Market Index: Serums |
|
|
|
|
€ 475,00 |
Editeur
: |
BizMiner |
Langue
: |
Anglais |
Date de publication : |
Juillet 2006 |
Taille du document : |
12 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Pharmaceutical Pricing Strategies
121 pages | Juillet 1998 |
Which pricing strategies will enable your company to maximise profitability? As healthcare cost-containment intensifies and pricing freedom is eroded, the need to develop new strategies to mainta |
795,00 €
|
| |
| |
Pharmaceutical Pricing Strategies 2000: Entering the new millennium
240 pages | Juin 2000 |
The favorable climate of the pharmaceutical sector has changed radically over the past ten years.
Where once a company's freedom over pricing decisions was almost limitless, external pressure |
955,00 €
|
| |
| |
Pain Therapeutics: A Strategic Re-evaluation.
198 pages | Août 2000 |
Pain management, though not a life-threatening disease, will have its proper place in the future healthcare system because the disability and economic loss in addition to personal suffering caused |
955,00 €
|
| |
| |
European Pharmaceutical Industry
35 pages | Juillet 2002 |
The Pharmaceutical industry remains one of Europe’s best performing sectors (employment, R&D and trade surplus).
The world pharmaceutical market was worth an estimated € 392,640 million (at ex-fact |
600,00 €
|
| |
| |
The Drug Discovery Outlook: Drivers of innovation in the 21st Century
189 pages | Octobre 2000 |
The Drug Discovery Outlook: Drivers of innovation in the 21st Century introduces and analyzes the five key enabling technologies and bioinformatics, which are currently driving pharmaceutical dru |
955,00 €
|
| |
| |
Healthcare In Scotland
52 pages | Mai 2000 |
The Scottish Presentation Includes:- The Structure Of The NHS In Scotland- The Funding Of The NHS In Scotland- Distribution Of The NHS Budget In Scotland- Segmentation Of Expenditure - Total Capital E |
327,00 €
|
| |
| |
The Drug Delivery Outlook to 2005
150 pages | Février 1999 |
Strategic overview : defines and values the market covered in the report, provides a macro analysis of the reasons why the drug delivery sector is growing at current rates and predicts how the c |
795,00 €
|
| |
| |
ePharmacies: Strategic Implications for the Healthcare Industry
230 pages | Mars 2000 |
Increasingly, the pharmaceutical sector is being influenced by the Internet.Are you in a position to:- Predict future shifts in drug prescribing and purchasing behavior?- Anticipate consolidation in b |
955,00 €
|
| |
| |
The Global Parallel Trade Outlook 2001 - 2006: A Country-by-Country Analysis
188 pages | Septembre 2001 |
Global Parallel Trade Outlook 2001: A country-by-country analysis, a new report by Reuters Business Insight, provides a detailed update on the status of parallel trade in the global marketplace.
1 200,00 €
|
|
| |
| |
Pfizer's Recent Takeover
15 pages | Juillet 2002 |
On 15th July 2002, Pfizer announced the acquisition of Pharmacia in a stock-for-stock transaction valued at $60 billion, expanding the company's core strengths in pharmaceuticals and health care.
|
300,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| US State Market Index: Serums |
|
|
The metrics in this report cover three year trends in Serums [Manufacturing sector], broken out on a state-by-state basis. Analysis is based on data applied from 13 industry firms. Industry market vitality measures for each state are benchmarked against US averages for the industry, creating easy comparison of state-by-state performance. Industry sales are detailed for both company-wide headquarters data and locally generated sales levels. The report also compares proprietary measures in each state and the US, including failure rates, entrepreneurial activity and new branch development rates in the industry.
|
|
State Market Index Contents
P1-3 Introduction and context for the measures
P4:Industry population and segmentation
P5:Establishment,company and branch failure rates
P6:Total industry sales volume (reported and locally generated)
P7:Average annual reported sales
P8:Average annual generated sales
P9:Startup activity, new branch development,employment concentration
P10:Overall Index
P11:About the data
|
|
|
PPLSEN
|
|
|
|
|
